Shoulder Innovations (NYSE: SI) reported Q2 2026 revenue of $17.2 million, up 56% from $11.0 million a year earlier, while GAAP diluted loss per share was $0.49 versus $165.53. Higher implant volume and pricing lifted gross margin to 78.3%, but commercial and product-development spending widened the operating loss to $10.0 million. The company raised its full-year revenue outlook to $67 million-$69 million.

Core financial results

Revenue growth reflected increases in implant systems sold and the number of customers. Gross profit rose faster than revenue as higher average selling prices and negotiated cost reductions added 2.1 percentage points to gross margin.

Profit measures moved in different directions. The operating loss widened as expenses increased, while the net loss narrowed because the prior-year quarter included a substantial fair-value charge.

The EPS comparison is not economically meaningful because weighted-average common shares increased to 20.7 million from approximately 116,000 in the prior-year period.

Implant volume and pricing drove revenue growth

Shoulder Innovations sold 2,238 implant systems during the quarter, approximately 50% more than a year earlier. Average selling price increased 5% to $7,674, meaning both volume and pricing contributed to the 56% revenue increase.

Management attributed the volume growth to onboarding new surgeons and increasing utilization among existing surgeons. The company also expanded its commercial organization to support the larger business.

During the quarter, Shoulder Innovations began the full commercial launches of its N-22 glenosphere for patients with metal hypersensitivity and a titanium plasma spray baseplate line extension for reverse procedures. The company did not quantify the revenue contribution from these products.

Gross margin improved, but expansion spending widened the operating loss

Gross profit increased by approximately $5.0 million, but combined SG&A and R&D expenses rose by approximately $9.2 million. SG&A increased 56% to $20.1 million because of commercial investments, higher variable selling costs, and public-company expenses. R&D increased 141% to $3.4 million, reflecting new product development and work related to a robotic-platform strategic partnership.

This expense growth caused the operating loss to widen by approximately $4.2 million despite the higher gross margin. The quarter therefore showed progress in sales and product economics, but not yet in operating leverage.

The narrower net loss largely resulted from total other expense falling to $0.1 million from $13.3 million. Q2 2025 included an $11.7 million charge related to changes in the fair value of the Series E purchase option. Because the company’s adjusted EBITDA definition does not add back that fair-value item, part of the reported adjusted EBITDA improvement also reflects the prior-year charge rather than only an improvement in underlying operations.

Liquidity and the balance sheet

Cash, cash equivalents, and marketable securities totaled $99.0 million at June 30, 2026, consisting of $24.5 million in cash and $74.5 million in marketable securities. That was approximately $25.3 million below the combined balance at December 31, 2025.

Long-term debt was $14.8 million, compared with $14.9 million at year-end. Shoulder Innovations also closed two credit facilities providing up to $50 million in aggregate capacity, refinancing existing debt and adding undrawn working-capital availability.

Full-year 2026 guidance

Shoulder Innovations raised both ends of its 2026 revenue range. The new midpoint is $68.0 million, approximately $1.5 million above the previous midpoint of $66.5 million.

With first-half revenue of $33.9 million, the updated range implies approximately $33.1 million-$35.1 million of revenue in the second half. That would place second-half revenue between roughly 2% below and 4% above the first-half result.

Recent insider transactions

Reported insider transactions included two sales by Gilde Healthcare Holding, a greater-than-10% holder, and a June sale by the chief operating officer. The CEO, CFO, and one director reported direct purchases in March totaling approximately $78,000; these transactions alone do not establish insiders’ views of the company’s outlook.

Risks investors need to watch

• Operating leverage remains unproven: SG&A grew in line with revenue, while R&D grew substantially faster, causing the operating loss to widen despite gross-margin expansion.
• Prior-year charges distort profit comparisons: The improvements in net loss and adjusted EBITDA were affected by a large Q2 2025 fair-value charge. Future comparisons may not benefit from the same base effect.
• Liquidity has declined while losses continue: Cash and marketable securities remain above reported debt, but their combined balance decreased by approximately $25.3 million from year-end.
• Growth depends on continued adoption: The raised outlook relies on further implant demand, surgeon onboarding, utilization by existing customers, and execution by the expanded commercial organization.

Summary

Shoulder Innovations’ Q2 2026 revenue growth was supported by higher implant volume, increased pricing, and a broader customer base, while cost reductions helped lift gross margin. However, increased commercial and R&D investment more than absorbed the additional gross profit and widened the operating loss. The main issues ahead are whether the company can deliver its raised revenue guidance, sustain its margin gains, and translate continued expansion into better operating leverage.

Find out more